China Resources Shuanghe (600062.SH) issued an announcement. Hunan Xiangzhong Pharmaceutical Co., Ltd., the company's holding subsidiary, received...
Zhitong Finance App News, China Resources Shuanghe (600062.SH) announced that Hunan Xiangzhong Pharmaceutical Co., Ltd., a holding subsidiary of the company, has received the “Notice of Approval of the Marketing Application for Chemical Ingredients” (Notice Numbers: 2024YS00939, 2024YS00941) for valproic acid and sodium valproate issued by the State Drug Administration.
Valproic acid is a medicine used to treat mental illness, mainly used to treat seizures and mania. Valproic acid APIs are approved to provide self-supply of raw materials for the production of valproic acid series products of Xiangzhong Pharmaceutical to ensure the quality and cost advantages of pharmaceutical products.
Sodium valproate is a medicine used to treat mental illness, mainly used to treat seizures and mania. The approval of sodium valproate raw materials can provide self-supply of raw materials for the production of sodium valproate series products of Xiangzhong Pharmaceutical to ensure the quality and cost advantages of pharmaceutical products.